Effects of β-Blockers with and Without Vasodilating Properties on Central Blood Pressure: Systematic Review and Meta-Analysis of Randomized Trials in Hypertension

Hypertension

Volumn 67, Issue 2, 2016, Pages 316-324

  Pucci, Giacomo ^a,b   Ranalli, Maria Giovanna ^a   Battista, Francesca ^a,b   Schillaci, Giuseppe ^a,b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Struttura Complessa di Medicina Interna   (Italy)

Author keywords

Antihypertensive agents; aortic blood pressure; beta adrenergic blockers; blood pressure; confidence intervals; heart rate; hypertension

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; DRUG EFFECT; DRUG EFFICACY; EFFECT SIZE; HEART RATE; HUMAN; HYPERTENSION; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; VASODILATATION; BLOOD PRESSURE; DRUG EFFECTS; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

ADRENERGIC BETA-ANTAGONISTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASODILATION;

EID: 84954405540     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.06467     Document Type: Article

References (71)

1. Mancia G, Fagard R, Narkiewicz K, et al; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357. doi: 10.1097/01. hjh.0000431740.32696.cc.
2. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520. doi: 10.1001/jama.2013.284427.
3. Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Mbewu A, Opie LH. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2012;11:CD002003. doi: 10.1002/14651858.CD002003.pub4.
4. Chen JM, Heran BS, Perez MI, Wright JM. Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension. Cochrane Database Syst Rev. 2010;1:CD007185.
5. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, Lemaitre RN, Wagner EH, Furberg CD. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA. 1997;277:739-745.
6. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 2003;21:1055-1076. doi: 10.1097/01.hjh.0000059044.65882.db.
7. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
8. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension A meta-analysis. Lancet. 2005;366:1545-1553. doi: 10.1016/S0140-6736(05)67573-3.
9. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006;174:1737-1742. doi: 10.1503/cmaj.060110.
10. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003. doi: 10.1016/S0140-6736(02)08089-3.
11. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906. doi: 10.1016/S0140-6736(05)67185-1.
12. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213-1225. doi: 10.1161/CIRCULATIONAHA.105.595496.
13. McEniery CM, Yasmin, McDonnell B, Munnery M, Wallace SM, Rowe CV, Cockcroft JR, Wilkinson IB; Anglo-Cardiff Collaborative Trial Investigators. Central pressure: variability and impact of cardiovascular risk factors: the Anglo-Cardiff Collaborative Trial II. Hypertension. 2008;51:1476-1482. doi: 10.1161/HYPERTENSIONAHA.107.105445.
14. Protogerou AD, Stergiou GS, Vlachopoulos C, Blacher J, Achimastos A. The effect of antihypertensive drugs on central blood pressure beyond peripheral blood pressure. Part II: Evidence for specific class-effects of antihypertensive drugs on pressure amplification. Curr Pharm Des. 2009;15:272-289.
15. Toda N. Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther. 2003;100:215-234.
16. Kelly R, Daley J, Avolio A, O'Rourke M. Arterial dilation and reduced wave reflection. Benefit of dilevalol in hypertension. Hypertension. 1989;14:14-21.
17. Mahmud A, Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens. 2008;21:663-667. doi: 10.1038/ajh.2008.156.
18. Kampus P, Serg M, Kals J, Zagura M, Muda P, Karu K, Zilmer M, Eha J. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension. 2011;57:1122-1128. doi: 10.1161/HYPERTENSIONAHA.110.155507.
19. Eguchi K, Hoshide S, Kario K. Effects of celiprolol and bisoprolol on blood pressure, vascular stiffness, and baroreflex sensitivity. Am J Hypertens. 2015;28:858-867. doi: 10.1093/ajh/hpu245.
20. Dhakam Z, Yasmin, McEniery CM, Burton T, Brown MJ, Wilkinson IB. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens. 2008;26:351-356. doi: 10.1097/HJH.0b013e3282f283c9.
21. Shah NK, Smith SM, Nichols WW, Lo MC, Ashfaq U, Satish P, Johnson JA, Epstein BJ. Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study). J Clin Hypertens (Greenwich). 2011;13:917-924. doi: 10.1111/j.1751-7176.2011.00549.x.
22. Briasoulis A, Oliva R, Kalaitzidis R, Flynn C, Lazich I, Schlaffer C, Bakris G. Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study. J Clin Hypertens (Greenwich). 2013;15:473-479. doi: 10.1111/jch.12118.
23. Eeftinck Schattenkerk DW, van den Bogaard B, Cammenga M, Westerhof BE, Stroes ES, van den Born BJ. Lack of difference between nebivolol/hydrochlorothiazide and metoprolol/hydrochlorothiazide on aortic wave augmentation and central blood pressure. J Hypertens. 2013;31:2447-2454. doi: 10.1097/HJH.0b013e328364fbca.
24. Studinger P, Tabák ÁG, Chen CH, Salvi P, Othmane TE, Torzsa P, Kapocsi J, Fekete BC, Tislér A. The effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial. J Clin Hypertens (Greenwich). 2013;15:910-917. doi: 10.1111/jch.12210.
25. Redón J, Pascual-Izuel JM, Rodilla E, Vicente A, Oliván J, Bonet J, Torguet JP, Calaforra O, Almirall J. Effects of nebivolol and atenolol on central aortic pressure in hypertensive patients: a multicenter, randomized, double-blind study. Blood Press. 2014;23:181-188. doi: 10.3109/08037051.2013.840421.
26. Koumaras C, Tziomalos K, Stavrinou E, Katsiki N, Athyros VG, Mikhailidis DP, Karagiannis A. Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. J Am Soc Hypertens. 2014;8:74-82. doi: 10.1016/j.jash.2013.09.001.
27. Casey DP, Curry TB, Joyner MJ, Charkoudian N, Hart EC. Acute-adrenergic blockade increases aortic wave reflection in young men and women: differing mechanisms between sexes. Hypertension. 2012;59:145-150. doi: 10.1161/HYPERTENSIONAHA.111.182337.
28. Adji A, Hirata K, Hoegler S, O'Rourke MF. Noninvasive pulse waveform analysis in clinical trials: similarity of two methods for calculating aortic systolic pressure. Am J Hypertens. 2007;20:917-922. doi: 10.1016/j.amjhyper.2007.03.006.
29. Hirata K, Vlachopoulos C, Adji A, O'Rourke MF. Benefits from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery J Hypertens. 2005;23:551-556.
30. Cockburn JA, Brett SE, Guilcher A, Ferro A, Ritter JM, Chowienczyk PJ. Differential effects of beta-adrenoreceptor antagonists on central and peripheral blood pressure at rest and during exercise. Br J Clin Pharmacol. 2010;69:329-335. doi: 10.1111/j.1365-2125.2009.03577.x.
31. Chen CH, Ting CT, Lin SJ, Hsu TL, Yin FC, Siu CO, Chou P, Wang SP, Chang MS. Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension. 1995;25:1034-1041.
32. Davis JT, Pasha DN, Khandrika S, Fung MM, Milic M, O'Connor DT. Central hemodynamics in prehypertension: effect of the-adrenergic antagonist nebivolol. J Clin Hypertens (Greenwich). 2013;15:69-74. doi: 10.1111/jch.12031.
33. Neal DA, Brown MJ, Wilkinson IB, Byrne CD, Alexander GJ. Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation. Transplantation. 2004;77:748-750.
34. van den Bogaard B, Immink RV, Westerhof BE, van Montfrans GA, van Lieshout JJ, van den Born BJ. Central versus peripheral blood pressure in malignant hypertension; effects of antihypertensive treatment. Am J Hypertens. 2013;26:574-579. doi: 10.1093/ajh/hps075.
35. Williams A, Kenny D, Wilson D, Fagenello G, Nelson M, Dunstan F, Cockcroft J, Stuart G, Fraser AG. Effects of atenolol, perindopril and verapamil on haemodynamic and vascular function in Marfan syndrome-a randomised, double-blind, crossover trial. Eur J Clin Invest. 2012;42:891-899. doi: 10.1111/j.1365-2362.2012.02668.x.
36. Asmar RG, London GM, O'Rourke ME, Safar ME; REASON Project Coordinators and Investigators. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension. 2001;38:922-926.
37. de Luca N, Asmar RG, London GM, O'Rourke MF, Safar ME; REASON Project Investigators. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. J Hypertens. 2004;22:1623-1630.
38. Soanker R, Naidu MU, Raju SB, Prasad AK, Rao TR. Effect of beta-1-blocker, nebivolol, on central aortic pressure and arterial stiffness in patients with essential hypertension. Indian J Pharmacol. 2012;44:407-411. doi: 10.4103/0253-7613.96349.
39. Vaz-de-Melo RO, Giollo-Júnior LT, Martinelli DD, Moreno-Júnior H, Mota-Gomes MA, Cipullo JP, Yugar-Toledo JC, Vilela-Martin JF. Nebivolol reduces central blood pressure in stage I hypertensive patients: experimental single cohort study. Sao Paulo Med J. 2014;132:290-296.
40. Kim EJ, Song WH, Lee JU, Shin MS, Lee S, Kim BO, Hong KS, Han SW, Park CG, Seo HS. Efficacy of losartan and carvedilol on central hemodynamics in hypertensives: a prospective, randomized, open, blinded end point, multicenter study. Hypertens Res. 2014;37:50-56. doi: 10.1038/hr.2013.112.
41. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006-1012. doi: 10.1016/j.jclinepi.2009.06.005.
42. Chen CH, Nevo E, Fetics B, Pak PH, Yin FC, Maughan WL, Kass DA. Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure. Validation of generalized transfer function. Circulation. 1997;95:1827-1836.
43. Pucci G, Cheriyan J, Hubsch A, Hickson SS, Gajendragadkar PR, Watson T, O'Sullivan M, Woodcock-Smith J, Schillaci G, Wilkinson IB, McEniery CM. Evaluation of the Vicorder, a novel cuff-based device for the noninvasive estimation of central blood pressure. J Hypertens. 2013;31:77-85. doi: 10.1097/HJH.0b013e32835a8eb1.
44. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2014. http://www.R-project.org/. Accessed on October 7, 2015.
45. Bates D, Maechler M, Bolker B, Walker S.-lme4: Linear mixed-effects models using Eigen and S4-. R package version 1.1-7. 2014. http://CRAN.R-project.org/package=lme4. Accessed on October 7, 2015.
46. Izzo JL Jr, Rajpal M, Karan S, Srikakarlapudi S, Osmond PJ. Hemodynamic and central blood pressure differences between carvedilol and valsartan added to lisinopril at rest and during exercise stress. J Am Soc Hypertens. 2012;6:117-123. doi: 10.1016/j.jash.2011.12.001.
47. Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens. 2006;19:214-219. doi: 10.1016/j.amjhyper.2005.08.007.
48. Pannier BM, Guerin AP, Marchais SJ, London GM. Different aortic reflection wave responses following long-term angiotensin-converting enzyme inhibition and beta-blocker in essential hypertension. Clin Exp Pharmacol Physiol. 2001;28:1074-1077.
49. Park S, Rhee MY, Lee SY, Park SW, Jeon D, Kim BW, Kwan J, Choi D. A prospective, randomized, open-label, active-controlled, clinical trial to assess central haemodynamic effects of bisoprolol and atenolol in hypertensive patients. J Hypertens. 2013;31:813-819. doi: 10.1097/HJH.0b013e32835e8f5b.
50. Zhou WJ, Wang RY, Li Y, Chen DR, Chen EZ, Zhu DL, Gao PJ. A randomized controlled study on the effects of bisoprolol and atenolol on sympathetic nervous activity and central aortic pressure in patients with essential hypertension. PLoS One. 2013;8:e72102. doi: 10.1371/journal. pone.0072102.
51. Boutouyrie P, Achouba A, Trunet P, Laurent S; EXPLOR Trialist Group. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension. 2010;55:1314-1322. doi: 10.1161/HYPERTENSIONAHA.109.148999.
52. Schneider MP, Delles C, Klingbeil AU, Ludwig M, Kolloch RE, Krekler M, Stumpe KO, Schmieder RE. Effect of angiotensin receptor blockade on central haemodynamics in essential hypertension: results of a randomised trial. J Renin Angiotensin Aldosterone Syst. 2008;9:49-56. doi: 10.3317/jraas.2008.003.
53. Radchenko GD, Sirenko YM, Kushnir SM, Torbas OO, Dobrokhod AS. Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial. Vasc Health Risk Manag. 2013;9:535-549. doi: 10.2147/VHRM.S44568.
54. Boutouyrie P, Bussy C, Hayoz D, Hengstler J, Dartois N, Laloux B, Brunner H, Laurent S. Local pulse pressure and regression of arterial wall hypertrophy during long-term antihypertensive treatment. Circulation. 2000;101:2601-2606.
55. Mackenzie IS, McEniery CM, Dhakam Z, Brown MJ, Cockcroft JR, Wilkinson IB. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension. 2009;54:409-413. doi: 10.1161/HYPERTENSIONAHA.109.133801.
56. London GM, Asmar RG, O'Rourke MF, Safar ME; REASON Project Investigators. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol. 2004;43:92-99.
57. Regnault V, Thomas F, Safar ME, Osborne-Pellegrin M, Khalil RA, Pannier B, Lacolley P. Sex difference in cardiovascular risk: role of pulse pressure amplification. J Am Coll Cardiol. 2012;59:1771-1777. doi: 10.1016/j.jacc.2012.01.044.
58. Benetos A, Thomas F, Joly L, Blacher J, Pannier B, Labat C, Salvi P, Smulyan H, Safar ME. Pulse pressure amplification a mechanical biomarker of cardiovascular risk. J Am Coll Cardiol. 2010;55:1032-1037. doi: 10.1016/j.jacc.2009.09.061.
59. Chirinos JA, Zambrano JP, Chakko S, Veerani A, Schob A, Willens HJ, Perez G, Mendez AJ. Aortic pressure augmentation predicts adverse cardiovascular events in patients with established coronary artery disease. Hypertension. 2005;45:980-985. doi: 10.1161/01. HYP.0000165025.16381.44.
60. McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson IB. Central blood pressure: current evidence and clinical importance. Eur Heart J. 2014;35:1719-1725. doi: 10.1093/eurheartj/eht565.
61. McGaughey TJ, Fletcher EA, Shah SA. Impact of antihypertensive agents on central systolic blood pressure and augmentation index: a meta-analysis [published online ahead of print August 19, 2015]. Am J Hypertens. doi:10.1093/ajh/hpv134. http://ajh.oxfordjournals.org/content/early/2015/08/19/ajh.hpv134. Accessed October 7, 2015.
62. Ding FH, Li Y, Li LH, Wang JG. Impact of heart rate on central hemodynamics and stroke: a meta-analysis of-blocker trials. Am J Hypertens. 2013;26:118-125. doi: 10.1093/ajh/hps003.
63. Manisty CH, Hughes AD. Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index. Br J Clin Pharmacol. 2013;75:79-92. doi: 10.1111/j.1365-2125.2012.04342.x.
64. Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep. 2007;9:269-277.
65. Ritter JM. Nebivolol: endothelium-mediated vasodilating effect. J Cardiovasc Pharmacol. 2001;38 Suppl 3:S13-S16.
66. Moser M, Frishman W. Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients. Am J Hypertens. 1998;11:15S-22S.
67. Riddell JG, Shanks RG, Brogden RN. Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris. Drugs. 1987;34:438-458.
68. Noda K, Oka M, Ma FH, Kitazawa S, Ukai Y, Toda N. Release of endothelial nitric oxide in coronary arteries by celiprolol, a beta(1)-adrenoceptor antagonist: possible clinical relevance. Eur J Pharmacol. 2001;415:209-216.
69. Papadopoulos CL, Kokkas B, Kotridis P, Karamouzis M, Haldoupi M, Platis A, Dadoush G, Kanonidis I. Effect of the beta 1-blocker/beta 2-agonist celiprolol on atrial natriuretic peptide plasma levels in hypertensive patients. Cardiovasc Drugs Ther. 1998;12:345-346.
70. Wilkinson IB, Qasem A, McEniery CM, Webb DJ, Avolio AP, Cockcroft JR. Nitric oxide regulates local arterial distensibility in vivo. Circulation. 2002;105:213-217.
71. Williams B, Lacy PS; CAFE and the ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) Investigators. Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate. J Am Coll Cardiol. 2009;54:705-713. doi: 10.1016/j.jacc.2009.02.088.